247 related articles for article (PubMed ID: 31692922)
41. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
42. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
[TBL] [Abstract][Full Text] [Related]
43.
Ahn JS; Kim HJ
Blood Res; 2022 Apr; 57(S1):32-36. PubMed ID: 35483923
[TBL] [Abstract][Full Text] [Related]
44. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory
Pandya BJ; Yang H; Schmeichel C; Qi CZ; Shah MV
J Med Econ; 2021; 24(1):19-28. PubMed ID: 33280474
[TBL] [Abstract][Full Text] [Related]
45. Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia.
Brinton LT; Sher S; Williams K; Canfield D; Orwick S; Wasmuth R; Cempre C; Skinner J; Lehman A; Blachly JS; Byrd JC; Lapalombella R
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545904
[TBL] [Abstract][Full Text] [Related]
46. Homoharringtonine Synergized with Gilteritinib Results in the Downregulation of Myeloid Cell Leukemia-1 by Upregulating UBE2L6 in FLT3-ITD-Mutant Acute Myeloid (Leukemia) Cell Lines.
Cai J; Huang H; Hu X; Lang W; Fu W; Xu L; Qiu Z; Zhong H; Chen F
J Oncol; 2021; 2021():3766428. PubMed ID: 34594375
[TBL] [Abstract][Full Text] [Related]
47. How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
Perrone S; Ottone T; Zhdanovskaya N; Molica M
Cancer Drug Resist; 2023; 6(2):223-238. PubMed ID: 37457126
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor.
Tse KF; Novelli E; Civin CI; Bohmer FD; Small D
Leukemia; 2001 Jul; 15(7):1001-10. PubMed ID: 11455967
[TBL] [Abstract][Full Text] [Related]
49. Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia.
Han H; Shin DY; Kim D; Kim H; Lee C; Koh Y; Hong J; Yoon SS
Leuk Lymphoma; 2020 Aug; 61(8):1932-1942. PubMed ID: 32374198
[TBL] [Abstract][Full Text] [Related]
50. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver TC; Hill JE; Rahmat L; Perl AE; Bahceci E; Mori K; Smith CC
Blood Adv; 2020 Feb; 4(3):514-524. PubMed ID: 32040554
[TBL] [Abstract][Full Text] [Related]
51. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia.
Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B
Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753
[TBL] [Abstract][Full Text] [Related]
52. Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation.
Chew S; Mackey MC; Jabbour E
Ther Adv Hematol; 2020; 11():2040620720930614. PubMed ID: 32547718
[TBL] [Abstract][Full Text] [Related]
53. Midostaurin: an emerging treatment for acute myeloid leukemia patients.
Gallogly MM; Lazarus HM
J Blood Med; 2016; 7():73-83. PubMed ID: 27186148
[TBL] [Abstract][Full Text] [Related]
54. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Nguyen B; Williams AB; Young DJ; Ma H; Li L; Levis M; Brown P; Small D
Oncotarget; 2017 Feb; 8(7):10931-10944. PubMed ID: 28077790
[TBL] [Abstract][Full Text] [Related]
55. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
[TBL] [Abstract][Full Text] [Related]
56. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.
Wang A; Wu H; Chen C; Hu C; Qi Z; Wang W; Yu K; Liu X; Zou F; Zhao Z; Wu J; Liu J; Liu F; Wang L; Stone RM; Galinksy IA; Griffin JD; Zhang S; Weisberg EL; Liu J; Liu Q
Oncotarget; 2016 May; 7(20):29131-42. PubMed ID: 27074558
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy.
Bocchia M; Carella AM; Mulè A; Rizzo L; Turrini M; Abbenante MC; Cairoli R; Calafiore V; Defina M; Gardellini A; Luzi G; Patti C; Pinazzi MB; Riva M; Rossi G; Sammartano V; Rigacci L
Pharmgenomics Pers Med; 2022; 15():393-407. PubMed ID: 35496349
[TBL] [Abstract][Full Text] [Related]
58. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.
Okada K; Nogami A; Ishida S; Akiyama H; Chen C; Umezawa Y; Miura O
Oncotarget; 2018 Feb; 9(10):8870-8886. PubMed ID: 29507660
[TBL] [Abstract][Full Text] [Related]
59. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
[TBL] [Abstract][Full Text] [Related]
60. Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat
Molica M; Perrone S; Rossi M
J Clin Med; 2023 May; 12(11):. PubMed ID: 37297842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
